In:
Frontiers in Immunology, Frontiers Media SA, Vol. 12 ( 2021-10-21)
Abstract:
Acute myeloid leukemia (AML) is a heterogeneous disease related to a broad spectrum of molecular alterations. The successes of immunotherapies treating solid tumors and a deeper understanding of the immune systems of patients with hematologic malignancies have promoted the development of immunotherapies for the treatment of AML. And high tumor mutational burden (TMB) is an emerging predictive biomarker for response to immunotherapy. However, the association of gene mutation in AML with TMB and immunological features still has not been clearly elucidated. In our study, based on The Cancer Genome Atlas (TCGA) and BeatAML cohorts, 20 frequently mutated genes were found to be covered by both datasets in AML. And TP53 mutation was associated with a poor prognosis, and its mutation displayed exclusiveness with other common mutated genes in both datasets. Moreover, TP53 mutation correlated with TMB and the immune microenvironment. Gene Set Enrichment Analysis (GSEA) showed that TP53 mutation upregulated signaling pathways involved in the immune system. In summary, TP53 mutation is frequently mutated in AML, and its mutation is associated with dismal outcome, TMB, and immunological features, which may serve as a biomarker to predict immune response in AML.
Type of Medium:
Online Resource
ISSN:
1664-3224
DOI:
10.3389/fimmu.2021.717527
DOI:
10.3389/fimmu.2021.717527.s001
DOI:
10.3389/fimmu.2021.717527.s002
DOI:
10.3389/fimmu.2021.717527.s003
DOI:
10.3389/fimmu.2021.717527.s004
DOI:
10.3389/fimmu.2021.717527.s005
DOI:
10.3389/fimmu.2021.717527.s006
DOI:
10.3389/fimmu.2021.717527.s007
DOI:
10.3389/fimmu.2021.717527.s008
DOI:
10.3389/fimmu.2021.717527.s009
DOI:
10.3389/fimmu.2021.717527.s010
DOI:
10.3389/fimmu.2021.717527.s011
DOI:
10.3389/fimmu.2021.717527.s012
DOI:
10.3389/fimmu.2021.717527.s013
DOI:
10.3389/fimmu.2021.717527.s014
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2021
detail.hit.zdb_id:
2606827-8
Bookmarklink